Safety and Pharmacology Study of BMS-866949

• Status: Terminated
• Trial end date: 2011-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to determine whether multiple doses.of BMS-886949 are safe and tolerable

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bristol-Myers Squibb

Criteria

Inclusion Criteria:

• Panels 1-6: Healthy Male Subjects

• Panel 7: Females

• Ages 21 to 55, inclusive

• Body Mass Index (BMI) of 18 to 32 kg/m², inclusive

• Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations

Exclusion Criteria:

• History of glaucoma or a confirmed intraocular pressure indicative of glaucoma at screening. (Normal IOP <21 mmHg)

• History or family history of psychiatric disorder

• Current treatment with prescription medication

• Exposure to any investigational drug or placebo within 12 weeks of study drug administration